Factors Influencing Peak Concentrations of Arbekacin in Patients

Ikeda, Keiko; Ikeda, Chie; Katoh, Katsuhiro; Tomiyama, Naoki; Matzno, Sumio; Matsuyama, Kenji; Okamura, Noboru

doi:10.5649/jjphcs.35.701

Cited by 2 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First, this study was retrospective. Regard to the limitation, our study did not evaluated ideal body weight as covariate on CL and V, while previous studies and guidelines recommended to consider the ideal body weight (and BMI) for adjustment of aminoglycoside dosage [9,19]. Additionally, we did not calculate CCr with ideal body weight instead of actual body weight.…”

Section: Discussionmentioning

confidence: 88%

Population pharmacokinetics of arbekacin in different infectious disease settings and evaluation of dosing regimens

Hagihara

Kato

Hamada

et al. 2016

Journal of Infection and Chemotherapy

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 88%

Population pharmacokinetics of arbekacin in different infectious disease settings and evaluation of dosing regimens

Hagihara

Kato

Hamada

et al. 2016

Journal of Infection and Chemotherapy

View full text Add to dashboard Cite

Clinical practice guidelines for therapeutic drug monitoring of arbekacin: A consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring

Okada

Kimura

Mikamo

et al. 2014

Journal of Infection and Chemotherapy

View full text Add to dashboard Cite

Arbekacin (ABK) was approved and widely used in Japan for treatment of patients infected with MRSA, and TDM was introduced in clinical practice. The Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring decided to develop a clinical practice guidelines for TDM of ABK for the following reasons. First, although the daily dose of 150-200 mg was approved in Japan, recent PK-PD studies revealed that higher serum concentration is required to achieve better clinical efficacy and several findings concerning the usefulness of higher dosage regimen have obtained recently. Second, although maximal concentrations that obtained immediately after the end of administration (Cmax) was generally adopted, the serum concentration at 1 h after initiation of administration [peak serum concentration (Cpeak)] proved to be more suitable as an efficacy indicator of aminoglycosides. Lastly, as ABK is approved only in Japan, no international practice guideline for TDM has not been available in ABK to date. This guideline evaluated the scientific data associated with serum ABK monitoring and provided recommendations based on the available evidence. Potential limitations of this guideline, however, include the findings that few prospective clinical trials of TDM of ABK are available in the treatment of MRSA infections and that most of the published literature describes observational studies.

show abstract

Factors Influencing Peak Concentrations of Arbekacin in Patients

Cited by 2 publications

References 4 publications

Population pharmacokinetics of arbekacin in different infectious disease settings and evaluation of dosing regimens

Population pharmacokinetics of arbekacin in different infectious disease settings and evaluation of dosing regimens

Clinical practice guidelines for therapeutic drug monitoring of arbekacin: A consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring

Contact Info

Product

Resources

About